eprintid: 10141411 rev_number: 21 eprint_status: archive userid: 608 dir: disk0/10/14/14/11 datestamp: 2022-01-10 15:15:12 lastmod: 2022-12-02 15:03:11 status_changed: 2022-12-02 15:03:10 type: article metadata_visibility: show creators_name: Khetan, R creators_name: Curtis, R creators_name: Deane, CM creators_name: Thorling Hadsund, J creators_name: Kar, U creators_name: Krawczyk, K creators_name: Kuroda, D creators_name: Robinson, SA creators_name: Sormanni, P creators_name: Tsumoto, K creators_name: Warwicker, J creators_name: Martin, A title: Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics ispublished: pub divisions: UCL divisions: B02 divisions: C08 divisions: D09 divisions: G03 keywords: Developability guidelines; biopharmaceutical informatics; developability assessment; computational prediction; antibody engineering; therapeutic antibodies. note: © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. abstract: Therapeutic monoclonal antibodies and their derivatives are key components of clinical pipelines in the global biopharmaceutical industry. The availability of large datasets of antibody sequences, structures, and biophysical properties is increasingly enabling the development of predictive models and computational tools for the “developability assessment” of antibody drug candidates. Here, we provide an overview of the antibody informatics tools applicable to the prediction of developability issues such as stability, aggregation, immunogenicity, and chemical degradation. We further evaluate the opportunities and challenges of using biopharmaceutical informatics for drug discovery and optimization. Finally, we discuss the potential of developability guidelines based on in silico metrics that can be used for the assessment of antibody stability and manufacturability. date: 2022-02-01 date_type: published publisher: Taylor & Francis official_url: https://doi.org/10.1080/19420862.2021.2020082 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1913162 doi: 10.1080/19420862.2021.2020082 lyricists_name: Martin, Andrew lyricists_id: ACRMA18 actors_name: Martin, Andrew actors_id: ACRMA18 actors_role: owner full_text_status: public publication: mAbs volume: 14 number: 1 article_number: 2020082 citation: Khetan, R; Curtis, R; Deane, CM; Thorling Hadsund, J; Kar, U; Krawczyk, K; Kuroda, D; ... Martin, A; + view all <#> Khetan, R; Curtis, R; Deane, CM; Thorling Hadsund, J; Kar, U; Krawczyk, K; Kuroda, D; Robinson, SA; Sormanni, P; Tsumoto, K; Warwicker, J; Martin, A; - view fewer <#> (2022) Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. mAbs , 14 (1) , Article 2020082. 10.1080/19420862.2021.2020082 <https://doi.org/10.1080/19420862.2021.2020082>. Green open access document_url: https://discovery-pp.ucl.ac.uk/id/eprint/10141411/1/Martin_Current%20advances%20in%20biopharmaceutical%20informatics%20guidelines%20impact%20and%20challenges%20in%20the%20computational%20developability%20assessment%20of%20antibody.pdf